There is exciting news for WMers in England, and hopeful news for those in Australia, as health agencies have recently approved ibrutinib for WM (England) and CLL/SLL (Australia).
The initial findings from WhiMSICAL, the first-of-its-kind patient- and researcher-led WM database will be presented at upcoming medical conferences. But, we need your help!
The Leukemia & Lymphoma Society is offering 3 one-hour programs addressing survivorship issues in October, November and December. You can participate by phone or online.
Now available online! CancerCare Webcast by Dr. Jorge Castillo (Dana-Farber Cancer Institute) and Dr. Jeffrey Matous (Colorado Blood Cancer Institute)
Our fellow blood cancer patient advocacy organization, the LLS, will now provide one-on-one assistance to WMers in the US on the entire clinical trial process.
This new booklet answers frequently asked questions about WM in language that is understandable for those who may not have a strong background in biology.
If you haven’t already registered, take advantage of CancerCare’s free phone/online WM workshop on October 4th, 2017. Pre-registration is required.
IWMF Plans for the IWMF Office and Employee Safety during Hurricane Irma.
Patient Worthy joins the list of IWMF global partner organizations.
Leopoldo (Polo) Peña was diagnosed with WM in February, 2017 at the age of 48. His experience in dealing with the disease, his treatment, and the care he received, helped him decide on the need for a Support Group in Mexico to help others who are living with WM.